


**Product Name** : BBO-8520  
**Cat. No.** : PC-22123  
**CAS No.** : 2893809-51-1  
**Molecular Formula** : C<sub>35</sub>H<sub>33</sub>F<sub>6</sub>N<sub>7</sub>O<sub>2</sub>S  
**Molecular Weight** : 729.75  
**Target** : Ras  
**Solubility** : 10 mM in DMSO



CAS: 2892613-01-1

## Biological Activity

BBO-8520 is a potent, selective and covalent inhibitor of **KRAS G12C** (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding. BBO-8520 binds in the switch II pocket and covalently modifies both the (ON) and (OFF) forms of KRASG12C independently of any other partner proteins. BBO-8520 inhibits KRASG12C (ON) by locking the GTP-bound protein in state 1. BBO-8520 displays highly significant binding to KRAS G12C in a global cysteine proteome analysis and is 100x more selective for KRASG12C than for WT KRAS and other mutant isoforms, with no measurable activity against N- or H-RAS. BBO-8520 has sub-nanomolar potency against KRASG12C mutant cell lines. BBO-8520 rapidly and completely blocks the RAS-RAF1 interaction in effector binding assays, at least 30x more potent than sotorasib and adagrasib at preventing outgrowth in long-term clonogenic assays. BBO-8520 (10 mg/kg, daily dosing, oral) causes significant tumor volume regression in the KrasG12C-p53 driven GEMM model, exhibits in vivo target engagement and pERK inhibition in the MIAPaCa-2 and H358 KRASG12C mutant tumor models.

## References

Anna E. Maciag, et al. *Cancer Res* (2024) 84 (7\_Supplement): ND07.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com